ESMO GI Highlights

Pemigatinib is an oral, potent, selective fibroblast growth factor receptor (FGFR)1-3 inhibitor that is currently approved for the treatment of adults with previously treated, unresectable, locally advanced/metastatic cholangiocarcinoma (CCA) bearing an FGFR2 fusion or other rearrangement based on the FIGHT-202 trial.

Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial (NCT03875235) demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 13.7 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 12.6 months).¹

Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial (NCT03875235) demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 13.7 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 12.6 months).¹

The randomized, open-label, multicenter, phase 3 ABC-06 trial established folinic acid/fluorouracil/oxaliplatin chemotherapy (FOLFOX) plus active symptom control (ASC) as the standard-of-care second-line treatment in patients with advanced biliary tract cancers (BTCs).¹

Although the clinical relevance of quality of life (QOL) is increasingly being acknowledged, it is rarely included as a clinical study end point in biliary tract cancers (BTCs).